Why the study?
Heart failure with preserved ejection fraction remains challenging to treat due to a paucity of clinical trials with specific therapies, which have mostly yielded neutral results.
This review highlights the challenges in treating HFpEF due to the lack of specific therapies with proven efficacy in clinical trials.
HFpEF management remains limited to comorbidities; leaves open the need for targeted therapies with proven efficacy.
Heart failure with preserved ejection fraction (HFpEF), often referred to as diastolic heart failure, remains one of the more challenging forms of heart failure to treat. This is a condition in which patients may or may not have signs and symptoms of heart failure, and retain a left ventricular ejection fraction greater than 50%. The challenge to treating HFpEF is due to the paucity of clinical trials with specific therapies, and those that have been completed have yielded relatively neutral results. This has resulted in treatments that are aimed more towards associated conditions, such as hypertension, rather than the underlying pathophysiology. This article will review the epidemiology and pathophysiology of HFpEF, and discuss the current therapeutic modalities, and clinical trials. In addition, we will discuss an ongoing clinical trial and the impact it may hold on future treatment options.
No takes yet. Share an insight, caveat, or question.
Goldstein et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: